Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View Full Press Release
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS